2004
Nonuniform Strut Distribution Correlates With More Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation
Takebayashi H, Mintz GS, Carlier S, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps E, Collins MB, Colombo A, Stone GW, Leon MB, Moses JW. Nonuniform Strut Distribution Correlates With More Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation. Circulation 2004, 110: 3430-3434. PMID: 15557367, DOI: 10.1161/01.cir.0000148371.53174.05.Peer-Reviewed Original ResearchConceptsMinimum lumen siteIntimal hyperplasiaLumen areaStent implantationStent strutsIH areaSmaller minimal lumen areaSirolimus-eluting stent implantationAmount of neointimaMinimum lumen areaMinimal lumen areaIVUS predictorsRestenosis patientsSES implantationRestenosis lesionsStent cellsStent strut distributionNeointimal hyperplasiaStrut distributionIntravascular ultrasoundMultivariate analysisVisible strutsComparison groupCross-sectional areaHyperplasiaSix- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer
Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJ. Six- and Twelve-Month Results From First Human Experience Using Everolimus-Eluting Stents With Bioabsorbable Polymer. Circulation 2004, 109: 2168-2171. PMID: 15123533, DOI: 10.1161/01.cir.0000128850.84227.fd.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnticoagulantsCatheterizationCineangiographyCoated Materials, BiocompatibleComorbidityCoronary AngiographyCoronary RestenosisCoronary StenosisDrug ImplantsEverolimusFemaleFollow-Up StudiesGrowth InhibitorsHumansHyperplasiaImmunosuppressive AgentsLactic AcidMaleMiddle AgedMyocardial InfarctionPolyestersPolymersProspective StudiesSingle-Blind MethodSirolimusStainless SteelStentsTreatment OutcomeTunica IntimaUltrasonography, InterventionalConceptsEverolimus-eluting stentsBare metal stentsRestenosis rateMajor adverse cardiac event ratesAdverse cardiac event ratesDe novo coronary lesionsMajor adverse cardiac eventsPercent neointimal volumeSegment restenosis rateAdverse cardiac eventsCardiac event rateNovo coronary lesionsStent restenosis rateTwelve-month resultsFirst human experienceIntravascular ultrasound analysisInitial clinical experienceLate stent malappositionLate stent thrombosisStent neointimal hyperplasiaSignificant reductionRestenosis reductionCardiac eventsI trialCoronary lesions
2002
7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth
Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, Lansky AJ, Stertzer SH, Yock PG, Fitzgerald PJ. 7-Hexanoyltaxol–Eluting Stent for Prevention of Neointimal Growth. Circulation 2002, 106: 1788-1793. PMID: 12356631, DOI: 10.1161/01.cir.0000031734.11420.1c.Peer-Reviewed Original ResearchConceptsBare metal stentsNeointimal growthIntravascular ultrasoundDe novo coronary lesionsAdjacent reference segmentsNovo coronary lesionsIndependent core laboratoryHuman feasibility studyNeointimal tissue growthIVUS substudyUnhealed dissectionConventional mechanical treatmentMulticenter trialCoronary lesionsRestenosis rateAtherosclerotic diseaseIntracoronary brachytherapyIVUS analysisNeointimal responseLong-term benefitsNeointimal thickeningStented segmentsCore laboratoryMetal stentsReference segments